Spago Nanomedical
LUND, SWEDEN / ACCESSWIRE / December 02, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today annouced that all patients have been recruited in the second dose group in the company's ongoing clinical phase I study SPAGOPIX-01 with the tumor-selective contrast agent SpagoPix (SND132D). New interim results are expected to be reported in early 2022.
A total of 6 patients with confirmed breast cancer have been included in the second dose group in the phase I study SPAGOPIX-01, which has been performed at two hospitals in Sweden. A number of adjustments to the study protocol have been made during the course of the study to, among other things, broaden the patient base and simplify the inclusion of patients. Including the 6 patients included in the first dose group, a total of 12 patients were evaluated in the study.
"It is very gratifying that we have now completed the recruitment and can start analyzing the results from the second patient group who received a higher dose of our tumor selective contrast agent SND132D", said Mats Hansen, CEO of Spago Nanomedical. "We have seen that SND132D is well tolerated by patients in lower doses, where early signals of contrast enhancement have also been shown. It will be exciting to get the results from the analysis of this dose group at the beginning of next year."
The primary endpoint of the study is to study safety at different doses of SN132D. Secondary endpoints include initially investigating how the contrast agent can enhance MRI images in clinical use in patients with solid tumors of the breast, as well as the liver and the pancreas.
Previous interim results from the study have shown a good safety profile and clear contrast in MRI images of breast tumors at the current dose. Furthermore, all images in the study showed a very good contrast in the pancreas and in the liver.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-02 10:34 CET.
Attachments
Second dose group fully recruited in Spago Nanomedical's phase 1 study with SpagoPix
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/675695/Second-Dose-Group-Fully-Recruited-in-Spago-Nanomedicals-Phase-1-Study-with-SpagoPix
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
EESystem Triumphs Again: Courts Deem Jason Shurka's Claims “Baseless” and “Futile”31.10.2025 14:25:00 CET | Press release
Judges Continue to Side with Energy Enhancement System as Jason Shurka's Legal Maneuvers Collapse LAS VEGAS, NV / ACCESS Newswire / October 31, 2025 /Energy Enhancement System, LLC ("EES") has achieved another decisive victory in its ongoing effort to defend truth, innovation, and integrity against baseless attacks from Jason Shurka and The Light System, Inc. ("TLS"). The United States District Court for the Eastern District of New York has formally granted EES permission to move forward with its full motion to dismiss - a strong indication that the court recognizes the legal and factual strength of EES's position. Judges in multiple jurisdictions have now described Shurka's filings as "baseless" and "futile," repeatedly returning the cases to the very courts where EES first initiated them - and where EES continues to win. Truth Over Deception The latest decision follows months of extensive filings exposing what EES alleges was a coordinated campaign of misinformation and brand confusi
TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations30.10.2025 21:00:00 CET | Press release
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 30, 2025 / TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO. CoNGO | TruMerit Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMerit CoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members. Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the Genera
Polaris Renewable Energy Announces Q3 2025 Results30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the nine and three months ended September 30, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS Third quarter consolidated energy production totaled 181,235 MWh, representing a 7% increase compared to 168,639 MWh in the same quarter last year. The increase is mainly attributable to the contribution from the Puerto Rican wind farm, acquired on March 3, 2025, which was not part of the portfolio in the comparative quarter of 2024, as well as stronger hydrologi
Polaris Renewable Energy Declares Quarterly Dividend30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on November 21st to shareholders of record at the close of business on November 10th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compan
Camino and Nittetsu Commence Proprietary Leaching Studies for Growth Opportunities at the Puquios Copper Project in Chile30.10.2025 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / :Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its joint venture with Nittetsu Mining Co., Ltd. ("Nittetsu") will initiate leaching studies at Nittetsu's metallurgical and chemical facility in Tokyo. These studies aim to assess the scalability of the Puquios Copper Project ("Puquios"or the "Project"). The Puquios mine is planned as a conventional sulphide leaching operation utilizing solvent extraction and electro winning ("SXEW") technology. All permits required for commencement of construction are in place, with mine construction anticipated in the first half of 2026. To support development, Camino and Nittetsu are actively pursuing a debt facility with a Japanese lender that is expected to offer highly competitive terms in the current mining finance environment. The first stage of the Puquios copper mine development is now on a path towards production. The Company is ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom